209 related articles for article (PubMed ID: 21925829)
1. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
Rollins KE; Peters CJ; Safranek PM; Ford H; Baglin TP; Hardwick RH
Eur J Surg Oncol; 2011 Dec; 37(12):1072-7. PubMed ID: 21925829
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Khanna A; Reece-Smith AM; Cunnell M; Madhusudan S; Thomas A; Bowrey DJ; Parsons SL
Dis Esophagus; 2014 Apr; 27(3):242-7. PubMed ID: 23651074
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy.
Marshall-Webb M; Bright T; Price T; Thompson SK; Watson DI
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27878904
[TBL] [Abstract][Full Text] [Related]
5. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
6. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial.
Slagter AE; Sikorska K; Grootscholten C; van Laarhoven HWM; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; van de Velde CJH; van Grieken NCT; van Sandick JW; Jansen EPM; Verheij M; Cats A
Cancer Med; 2020 Sep; 9(18):6609-6616. PubMed ID: 32735752
[TBL] [Abstract][Full Text] [Related]
8. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.
Khorana AA; Dalal M; Lin J; Connolly GC
Cancer; 2013 Feb; 119(3):648-55. PubMed ID: 22893596
[TBL] [Abstract][Full Text] [Related]
9. Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial.
Lygidakis NJ; Sgourakis G; Aphinives P
Hepatogastroenterology; 1999; 46(27):2035-8. PubMed ID: 10430393
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
11. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Starling N; Rao S; Cunningham D; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR
J Clin Oncol; 2009 Aug; 27(23):3786-93. PubMed ID: 19398575
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
Forshaw MJ; Gossage JA; Chrystal K; Cheong K; Atkinson S; Botha A; Harper PG; Mason RC
Eur J Surg Oncol; 2006 Dec; 32(10):1114-8. PubMed ID: 16621430
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge.
Fanikos J; Rao A; Seger AC; Piazza G; Catapane E; Chen X; Goldhaber SZ
Am J Med; 2011 Dec; 124(12):1143-50. PubMed ID: 22114828
[TBL] [Abstract][Full Text] [Related]
15. The risk of venous thromboembolism after surgery for esophagogastric malignancy and the impact of chemotherapy: a population-based cohort study.
Adiamah A; Ban L; West J; Humes DJ
Dis Esophagus; 2020 Jun; 33(6):. PubMed ID: 31617892
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism in advanced ovarian cancer patients undergoing frontline adjuvant chemotherapy.
Pant A; Liu D; Schink J; Lurain J
Int J Gynecol Cancer; 2014 Jul; 24(6):997-1002. PubMed ID: 24905613
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Risk Factors Related to Symptomatic Venous Thromboembolic Events After Esophagectomy for Cancer.
Mantziari S; Gronnier C; Pasquer A; Gagnière J; Théreaux J; Demartines N; Schäfer M; Mariette C;
Ann Thorac Surg; 2016 Sep; 102(3):979-984. PubMed ID: 27262916
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
[TBL] [Abstract][Full Text] [Related]
19. Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial.
Song KY; Yoo HM; Kim EY; Kim JI; Yim HW; Jeon HM; Park CH
Ann Surg Oncol; 2014 Dec; 21(13):4232-8. PubMed ID: 25012265
[TBL] [Abstract][Full Text] [Related]
20. Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study.
Kim JS; Kim MA; Oh DY; Lee SH; Kim DW; Im SA; Kim WH; Yang HK; Heo DS; Bang YJ; Lee KU; Kim TY; Kim TM; Kim NK; Choe KJ
Jpn J Clin Oncol; 2011 Feb; 41(2):245-52. PubMed ID: 21106599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
